VKV. O. Kusakina

V. O. Kusakina

*This is an algorithmically generated author record based on publicly available information.

V. O. Kusakina has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Estimation of the socio-economic burden of obesity in the Russian Federation

    by L. Yu. Gorbachenko, K. I. Matrenin, A. A. Slabikova, R. A. Teryan, D. N. Pustovalov, N. S. Giliazetdinova, I. A. Mikhailov, U. N. Dmitrieva, N. E. Usacheva, O. S. Golikova, et al.

    Objective : To estimate the direct medical costs associated with the treatment of adult patients with obesity in the Russian Federation, including the costs of pharmacotherapy for obesity, management of comorbidities and hospitalizations due to specific obesity-related complication. Material and methods. A mathematical model was developed to analyze the direct medical costs of pharmacotherapy for obesity and related comorbidities over a 1-year time horizon. The analysis included adults aged 18–69 years with obesity (body mass index (BMI) ≥30 kg/m²); a subgroup of individuals with BMI ≥35 kg/m² was analyzed separately. The target population size was determined using national epidemiological data, stratified by sex, age, and obesity class. The model evaluated the costs of pharmacotherapy for obesity, management of comorbid conditions, and hospitalizations associated with type 2 diabetes mellitus, coronary heart disease, and arterial hypertension. Treatment costs were calculated based on dosing regimens, the State Register of Maximum Selling Prices, and public procurement data; hospitalization costs were estimated using diagnosis-related groups. Results . The estimated number of adults with obesity was 21.64 million, including 5.45 million individuals with BMI ≥35 kg/m². In the modeled scenario of universal drug coverage, annual pharmacotherapy costs were estimated at 3.1 trillion rubles for the overall population and 778 billion rubles for the subgroup with BMI ≥35 kg/m². The estimated number of comorbidity cases was 4.44 million for coronary heart disease, 15.2 million for arterial hypertension, and 7.03 million for type 2 diabetes mellitus. Pharmacotherapy costs for these conditions amounted to 69, 324, and 396 billion rubles, respectively. Annual hospitalization costs were estimated at 377 billion rubles for type 2 diabetes mellitus and 89 billion rubles for coronary heart disease. Conclusion . The management of adults with obesity and comorbid conditions within the Russian healthcare system is associated with substantial direct medical costs. Reducing this burden requires a combination of prevention, early detection, and long-term patient management.

  • Open Access

    Analysis of years of life lost due to premature cancer mortality in the Russian Federation

    by Zh. V. Khailova, A. D. Kaprin, V. V. Omelyanovsky, D. N. Pustovalov, Yu. A. Agafonova, V. O. Kusakina, S. A. Ivanov, P. V. Shegai

    Background. Burden of disease estimation allows analyses to be carried out integrally, including cause and effect assessment. the rate of life years lost due to premature mortality is part of the burden of disease analysis. given that the burden of cancer is steadily increasing, analysis of the number of years lost makes it possible to identify new strategic directions, as well as to adjust decisions already made, in the health care of cancer patients.Purpose: to estimate the loss of life expectancy as a result of premature mortality from cancer in the population of the Russian Federation.Material and Methods. the analysis was carried out using international statistical databases for disease burden estimation, databases of the Federal state statistics service (Rosstat). to determine the target groups of priority reduction of mortality from neoplasms in the Russian Federation, an estimation of the lost years of life expectancy as a result of premature mortality in the form of the e† (e-dagger) indicator was carried out. the analyzed period of the study was 2010–2019.Results. the Russian Federation is characterized by the smallest share of losses from cancer in the structure of losses from all causes of death compared to the analyzed countries (Japan, France, germany, latvia, lithuania, estonia). However, the share of losses has been intensively increasing for 10 years (in 2010 – 14.79 %, in 2019 – 17.54 %). in comparison with the analyzed countries, Russia is more characterised by losses from cancer at a younger age, with the highest value of life years lost in the age group 60–64 years. the age-standardized number of years lost in men in Russia is 67.1 % higher than in women. in the age group from 25 to 49 years of age, the loss of life expectancy due to cancer in women is higher and accounts for 0.4 years (or 19 %) of all losses, which is not typical of other age groups in which losses in men prevail. A significant regional differentiation of mortality in the constituent entities of the Russian Federation has been revealed, which is also reflected in the number of years lost.Conclusion. the potential of preventive strategies in the Russian Federation has not been fully realized – the loss of life years in young and middle age requires the correction of measures to improve preventive services and oncological care. the revealed regional differentiation allows us to identify regions with high losses for priority solutions.